{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:03:56Z","timestamp":1762527836208,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005242","name":"Heed Ophthalmic Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ajoc.2020.100868","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T02:45:30Z","timestamp":1597286730000},"page":"100868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Necrotizing myositis in a rectus muscle arising in the setting of long-standing Langerhans cell histiocystosis and recent dabrafenib treatment"],"prefix":"10.1016","volume":"20","author":[{"given":"Suzanne W.","family":"van Landingham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Puccetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli L.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Lucarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ajoc.2020.100868_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1021\/ml4000063","article-title":"Discovery of dabrafenib: a selective inhibitor of raf kinases with antitumor activity against B-Raf-Driven tumors","volume":"4","author":"Rheault","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.ajoc.2020.100868_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618767611","article-title":"Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience","volume":"12","author":"Khunger","year":"2018","journal-title":"Ther Adv Respir Dis"},{"issue":"9","key":"10.1016\/j.ajoc.2020.100868_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091262","article-title":"BRAF mutations and the utility of RAF and MEK inhibitors in primary brain tumors","volume":"11","author":"Schreck","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.ajoc.2020.100868_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070943","article-title":"A systematic review of phase II targeted therapy clinical trials in anaplastic thyroid cancer","volume":"11","author":"Ljubas","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"Suppl 1","key":"10.1016\/j.ajoc.2020.100868_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/hon.2594","article-title":"New treatment options in hairy cell leukemia with focus on BRAF inhibitors","volume":"37","author":"Falini","year":"2019","journal-title":"Hematol Oncol"},{"issue":"3","key":"10.1016\/j.ajoc.2020.100868_bib8","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600-mutant erdheim-chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ajoc.2020.100868_bib9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/asheducation-2015.1.565","article-title":"Treatment of Langerhans cell histiocytosis: role of BRAF\/MAPK inhibition","volume":"2015","author":"Abla","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"31","key":"10.1016\/j.ajoc.2020.100868_bib10","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.19.00456","article-title":"Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study","volume":"37","author":"Donadieu","year":"2019","journal-title":"J Clin Oncol"},{"author":"Dabrafenib package insert","key":"10.1016\/j.ajoc.2020.100868_bib11"},{"issue":"25","key":"10.1016\/j.ajoc.2020.100868_bib12","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","article-title":"Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis","volume":"121","author":"Gadner","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ajoc.2020.100868_bib13","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/cncr.31348","article-title":"CNS Langerhans cell histiocytosis: common hematopoietic origin for LCH-associated neurodegeneration and mass lesions","volume":"124","author":"McClain","year":"2018","journal-title":"Cancer"},{"issue":"7672","key":"10.1016\/j.ajoc.2020.100868_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature23672","article-title":"A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease","volume":"549","author":"Mass","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ajoc.2020.100868_bib15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3960\/jslrt.56.109","article-title":"Langerhans cell histiocytosis and Langerhans cell sarcoma: current understanding and differential diagnosis","volume":"56","author":"Nakamine","year":"2016","journal-title":"J Clin Exp Hematop"},{"issue":"3","key":"10.1016\/j.ajoc.2020.100868_bib16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ajoc.2020.100868_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/ICU.0000000000000295","article-title":"Orbital sarcomas in retinoblastoma patients: recommendations for screening and treatment guidelines","volume":"27","author":"Baker","year":"2016","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajoc.2020.100868_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1573397114666180406101850","article-title":"Immune mediated necrotizing myopathy: where do we stand?","volume":"15","author":"Mohammed","year":"2019","journal-title":"Curr Rheumatol Rev"},{"issue":"3","key":"10.1016\/j.ajoc.2020.100868_bib19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.autrev.2018.09.008","article-title":"Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy","volume":"18","author":"Anquetil","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.ajoc.2020.100868_bib20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/acr.22920","article-title":"Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle","volume":"69","author":"Pinal-Fernandez","year":"2017","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"4","key":"10.1016\/j.ajoc.2020.100868_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jsha.2019.08.001","article-title":"Statin-induced necrotizing autoimmune myopathy: an uncommon complication of a commonly used medication","volume":"31","author":"Saleh","year":"2019","journal-title":"J Saudi Heart Assoc"},{"issue":"1","key":"10.1016\/j.ajoc.2020.100868_bib22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s13311-015-0394-2","article-title":"Immunotherapies for immune-mediated myopathies: a current perspective","volume":"13","author":"Needham","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.ajoc.2020.100868_bib23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.nmd.2020.02.003","article-title":"Clinical and histological features of immune-mediated necrotising myopathy: a multi-centre South Australian cohort study","volume":"30","author":"Day","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"10.1016\/j.ajoc.2020.100868_bib24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.5692\/clinicalneurol.cn-001270","article-title":"[A case of anti-titin antibody positive nivolumab-related necrotizing myopathy with myasthenia gravis]","volume":"59","author":"Isami","year":"2019","journal-title":"Rinsho Shinkeigaku"},{"issue":"136","key":"10.1016\/j.ajoc.2020.100868_bib25","first-page":"75","article-title":"Triggers of inflammatory myopathy: insights into pathogenesis","volume":"25","author":"Adler","year":"2018","journal-title":"Discov Med"},{"key":"10.1016\/j.ajoc.2020.100868_bib26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Canc"},{"issue":"2","key":"10.1016\/j.ajoc.2020.100868_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/IOP.0000000000001429","article-title":"Orbital myositis: a comprehensive review and reclassification","volume":"36","author":"McNab","year":"2020","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"8","key":"10.1016\/j.ajoc.2020.100868_bib28","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/rheumatology\/key080","article-title":"Steroid refractory dermatomyositis following combination dabrafenib and trametinib therapy","volume":"57","author":"Harrison","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.ajoc.2020.100868_bib29","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2017-03-771873","article-title":"Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)","volume":"130","author":"Cohen Aubart","year":"2017","journal-title":"Blood"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993620301833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993620301833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:58:41Z","timestamp":1762527521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993620301833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":27,"alternative-id":["S2451993620301833"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2020.100868","relation":{},"ISSN":["2451-9936"],"issn-type":[{"type":"print","value":"2451-9936"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Necrotizing myositis in a rectus muscle arising in the setting of long-standing Langerhans cell histiocystosis and recent dabrafenib treatment","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2020.100868","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100868"}}